sheriff Grover schreef op 17 januari 2019 19:55:
[...]
Hmmm Nu maar van harte hopen dat ze niet alles in de verkoop gooien , daar moet ik even niet aan denken dat er 3 miljoen aandelen op de markt komen ..... Never a dull moment @ Genmab !
Major Shareholder Announcement
Company Announcement
• Major shareholder announcement for Genmab A/S
Copenhagen, Denmark; January 17, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of October 11, 2018, BlackRock, Inc. has decreased their total ownership (indirectly owned shares and financial instruments) in Genmab A/S to below 5% of the share capital and voting rights in Genmab A/S.
This adds additional information to the company announcement no. 24/2018, when it was announced that BlackRock, Inc. as of August 8, 2018 held indirectly via shares 4.94% of the share capital and voting rights in Genmab A/S. At that time BlackRock, Inc. also held via financial instruments 0.36% of the shares and voting rights in Genmab A/S resulting in a total of 5.30% of the shares and voting rights in Genmab A/S.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; E:
rcg@genmab.com